allogeneic Eng gd eTCR T (Immatics/Brostol-Myers Squibb)

N/A

Report date: 2025/06/11 10:59:06

Base Information

Drug Nameallogeneic Eng gd eTCR T (Immatics/Brostol-Myers Squibb)
Drug Alias NameTCR T cell therapy (Immatics/Brostol-Myers Squibb)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHuman leukocyte antigen modulatorsT lymphocytes stimulantsImmunostimulants
TargetsHuman leukocyte antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImmatics NV
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb CompanyImmatics NV
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A